Previous 10 | Next 10 |
PLANEGG / MUNICH, GERMANY / ACCESSWIRE / Janauary 10, 2022 / MorphoSys AG (FSE:MOR; NASDAQ:MOR), announced today that Jean-Paul Kress, M.D., Chief Executive Officer of MorphoSys, will present at the 40 th Annual J.P. Morgan Healthcare Conference on Wednesday January 12, 2022 at 5:15 p.m. E...
MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosis Data presented during poster and oral sessions at the 63 rd American Society of Hematology Annual Meeting and Exposition Latest results from the...
RE-MIND2 compared patient outcomes from pivotal L-MIND study with matched patient populations treated with NCCN/ESMO recommended therapies Results from the retrospective cohort analysis indicate significant overall survival improvement compared with Pola-BR and R2 ...
- RE-MIND2 compared patient outcomes from pivotal L-MIND study with matched patient populations treated with NCCN/ESMO recommended therapies - Results from the retrospective cohort analysis indicate significant overall survival improvement compared with Pola-BR and R2 BOSTON, MA and...
The biotechnology sector largely underperformed the broader market this year, particularly small- to mid-cap biotech indexes whose constituents tend to experience more volatility. Contributing factors to the market decline include fears of increased regulation and oversight of M&A...
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 29, 2021 / Corporate Calendar 2022 Dear Madam/Sir, Please note MorphoSys' financial reporting dates 2022 as follows: Publication of Interim Statement / Report Conference Call Year-End Results 2021 March 16, 2022 // 10 pm CET (5 pm EDT...
Wells Fargo upgrades Matador Resources (MTDR -3.7%) to Overweight from Equal Weight with a $53 price target, and raises Callon Petroleum (CPE -6.4%) to Equal Weight from Underweight with a $75 target, seeing energy entering a new "super cycle" in 2022 with U.S. E&Ps as the "tip of the spe...
Image source: The Motley Fool. MorphoSys AG (NASDAQ: MOR) Q3 2021 Earnings Call Nov 11, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: MorphoSys AG (MOR) Q3 2021 Earnings Call Transcript
MorphoSys AG (MOR) Q3 2021 Results Earnings Conference Call November 11, 2021, 08:00 AM ET Company Participants Julia Neugebauer - Senior Director, Investor Relations Jean-Paul Kress - Chief Executive Officer Malte Peters - Chief Research and Development Officer Sung Lee - Chief Financial Off...
The following slide deck was published by MorphoSys AG in conjunction with their 2021 Q3 earnings call. For further details see: MorphoSys AG 2021 Q3 - Results - Earnings Call Presentation
News, Short Squeeze, Breakout and More Instantly...
MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that it has formally notified the Nasdaq Stock Market of its intention to voluntarily delist its American Depositary Shares (“ADSs”) from the Nasdaq Global Market and to deregister the ADSs under Section 12(b) of the Securities Ex...
MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that the company has entered into a delisting agreement with Novartis BidCo AG and Novartis AG following the successful closing of the acquisition of MorphoSys by Novartis in May 2024. Novartis BidCo Germany AG (together with Novartis BidCo AG ...
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 20, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announces that Novartis BidCo Germany AG informed the MorphoSys AG Management Board of its intention to merge MorphoSys AG as transferring company into Novartis BidCo Germany AG. Novartis BidCo Germany ...